©

2019 Mursla Ltd.

Hauser Forum, 3 Charles Babbage Rd CB3 0GT, Cambridge, U.K.

  • LinkedIn - White Circle
  • White Facebook Icon

Solutions

Point-of-care multiplex diagnostics system

Market: Cancer liquid biopsy

Existing and promising circulating biomolecules in our pipeline (2)

Addressable

market size (1)

Breast cancer

Lung cancer

Theragnostics

Treatment strategy that combines therapeutics with diagnostics

$2BN

Protein HER2, ER, PR, KI-67, p53, PIK3CA

Exosome HER2 

Protein EGFR, PDL1

Exosome EGFR, EGFR L858R, EGFR del 19 (3)

Monitoring therapy

Protein HER2, CA15-3, CA.27.29, CEA

Tracking potential drug resistance and therapeutic response during therapy

$5BN

Protein EGFR, PDL1

Exosome EGFR, EGFR T790M (3)

Prognosis

Predicting the likely course of disease

$4-7BN

Protein HSP90A, CA15-3, PAI-1

PDL1

Screening

Testing the general population to detect cancer among asymptomatic patients

$7-9BN

Pan cancer approach

See first studies with CancerSEEK panel

1. Estimates for developed countries.

2. New circulating biomolecules for liquid biopsy (that are specific to the disease) are being discovered.

3. Mutations are ideally considered at the proteomic level instead of DNA due to risk of false positives among other things. Mutant protein solubility is enhanced by exosomes when freely circulating form is not stable.

Market: Alzheimer disease

Promising circulating biomolecules in our pipeline (2)

Addressable

market size (1)

Companion diagnostics
Early detection

No drugs approved yet for Alzheimer disease.

Alzheimer patients reached 47 million in 2016.

A more personalized approach to treatment is needed by focusing on circulating biomolecules correlated with the disease, if possible non-invasively.

>$10BN

Protein amyloid beta 40, amyloid beta 42, Tau, p-Tau

Exosome amyloid beta, p-Tau

1. Estimates for developed countries.

2. New circulating biomolecules for Alzheimer disease (that are specific to the disease) are being discovered.